Comparing HAMD17 and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials-Reference-Cited by-同舟云学术

Comparing HAMD17 and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials

Published:2013-03 Issue:3 Volume:145 Page:363-369
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Boessen Ruud,Groenwold Rolf H.H.,Knol Mirjam J.,Grobbee Diederick E.,Roes Kit C.B.

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference25 articles.

1. The Hamilton depression rating scale: has the gold standard become a lead weight?;Bagby;American Journal of Psychiatry,2004

2. Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD);Ballesteros;Journal of Affective Disorders,2007

3. Quantitative rating of depressive states;Bech;Acta Psychiatrica Scandinavica,1975

4. The Hamilton depression scale. Evaluation of objectivity using logistic models;Bech;Acta Psychiatrica Scandinavica,1981

5. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes;Bech;Acta Psychiatrica Scandinavica,1986

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Heart rate variability, a potential assessment tool for identifying anxiety, depression, and sleep disorders in elderly individuals;2024-08-20

2. Identification of a strong genetic risk factor for major depressive disorder in the human virome;iScience;2024-03

3. Factor structure of the patient health questionnaire-9 and measurement invariance across gender and age among Chinese university students;Medicine;2023-01-06

4. Efficacy and safety of Gyejibokryeong-hwan (GBH) in major depressive disorder: study protocol for multicentre randomised controlled trial;Trials;2022-06-01

5. Randomized Controlled Trials and the Efficacy of Psychotropic Medications;NeuroPsychopharmacotherapy;2022